Overview
- Several plaintiff firms including Kaplan Fox, Bronstein Gewirtz & Grossman, Rosen Law and Levi & Korsinsky have filed or solicited investors and warned that any investor seeking lead-plaintiff status must move the court by October 5, 2026.
- The complaints cover purchasers of ARS securities from March 9, 2026 through June 24, 2026 and allege the company made false or misleading statements about when CVS Caremark would add neffy to its formulary.
- Plaintiffs cite ARS’s June 24, 2026 press release saying no new formulary additions were issued for the July 1 cycle and link that disclosure to a roughly 23.9% one-day stock drop on June 25, 2026.
- No class has been certified and the allegations remain unproven, so investors are not represented by court-appointed counsel unless they retain one or are named lead plaintiff.
- The suits focus on payer access because CVS Caremark formulary timing can determine real-world patient access and summer sales, and a finding for plaintiffs could trigger damage claims, extended discovery into ARS‑Caremark communications, and business disruption for ARS.